Navigation Links
DHHS Guidelines Support Use of Trofile(TM) Assay Prior to CCR5 Inhibitor Use
Date:2/4/2008

reatment regimens for their patients that lead to better outcomes and reduced costs. The Company's technology is also being used by numerous biopharmaceutical companies to develop new and improved antiviral therapeutics and vaccines as well as targeted cancer therapeutics. More information about the Company and its technology can be found on its web site at http://www.monogrambio.com.

Forward-Looking Statements

Certain statements in this press release are forward-looking. These forward-looking statements include references to the demand for our Trofile Assay, the potential use of our Trofile Assay for patient selection for the class of HIV drugs known as CCR5 antagonists, the size and timing of our customers' clinical trials utilizing our products, the outlook for the CCR5 class of drugs and our Trofile Assay, the number of patients each year in the U.S. who potentially could be candidates for new classes of HIV drugs such as CCR5 antagonists, expected protection provided by patents, possible regulation of Trofile and our other products by the FDA. These forward-looking statements are subject to risks and uncertainties and other factors, which may cause actual results to differ materially from the anticipated results or other expectations expressed in such forward-looking statements. These risks and uncertainties include, but are not limited to: the risk that physicians may not use a molecular diagnostic for patient selection for CCR5 antagonists or other HIV drugs; whether larger confirmatory clinical studies will confirm the results of initial studies; risks and uncertainties relating to the performance of our products; the growth in revenues; the size, timing and success or failure of any clinical trials for CCR5 inhibitors, entry inhibitors or integrase inhibitors; the risk that our Trofile Assay may not be utilized for patient use with CCR5 inhibitors; our ability to successfully conduct clini
'/>"/>

SOURCE Monogram Biosciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Ranexa(R) Added to New ACC/AHA Guidelines on Unstable Angina/Non ST-Elevation Myocardial Infarction (UA/NSTEMI)
2. Interim Analysis Supports Continuation of Cell Genesys VITAL-1 Phase 3 Clinical Trial of GVAX Immunotherapy for Prostate Cancer
3. Interim Safety Analysis Supports Continuation of Allos Therapeutics Pivotal Phase 2 PROPEL Trial of PDX in Patients with Peripheral T-cell Lymphoma
4. PNH Patients With Lower Levels of Hemolysis, Mild Anemia and Minimal Transfusion Support Have Significant Disease Burden; Soliris(R) Therapy Provided Clinical Improvements in PNH Patients Regardless of Disease Severity
5. New Data to Support VELCADE(R) (Bortezomib) For Injection Based Therapies as Setting New Standards in The Care of Newly Diagnosed Patients With Multiple Myeloma
6. Pharsight Uses FDA Disease Model to Support Oncology Drug Development
7. Powerful New Efficacy Data in Moderate and Severe Hypertensive Patients Supports FDA Approval of AVALIDE(R) (Irbesartan-Hydrochlorothiazide) as the First Combination Therapy for Initial Use in Patients Likely to Need Multiple Drugs to Achieve Their Blood
8. New Data from the Framingham Heart Study Supports PAT Technology to Diagnose Early Cardiovascular Disease
9. Cost-Effectiveness Study Supports Use of EUFLEXXA(TM) by Rheumatologists for Pain Relief in Patients with Knee Osteoarthritis
10. Consumer Advocates Support Patent Office on Stem Cell Patent Rejection
11. SAIC Awarded Malaria Vaccine Production Support Contract Extension by the National Institute of Allergy and Infectious Diseases
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/1/2015)... N.J. , July 1, 2015  Echo ... device company focused on non-invasive continuous glucose monitoring ... its new and completely re-designed corporate website ... intuitive access to Echo,s technology and enhances the ... The new website better communicates to prospective customers ...
(Date:7/1/2015)... HEIGHTS, Utah , July 1, 2015 /PRNewswire/ ... ), a manufacturer and marketer of rehabilitation and ... completed its $4,025,000 private placement financing led by ... strategic private equity investor focused on the healthcare ... to promote organic growth and pursue potential strategic ...
(Date:7/1/2015)... , July 1, 2015 ExeGi Pharma, ... and probiotic treatments, announced today that it has been ... and Non-prescription Health Products Directorate (NNHPD) to sell Visbiome™ ... Visbiome was developed by Professor Claudio De Simone ... extensive clinical investigation. Professor De Simone recently signed an ...
Breaking Medicine Technology:Echo Therapeutics Announces New Website Launch 2Echo Therapeutics Announces New Website Launch 3Dynatronics Announces Completion Of $4,025,000 Private Placement Led By Prettybrook Partners 2Dynatronics Announces Completion Of $4,025,000 Private Placement Led By Prettybrook Partners 3ExeGi Pharma Secures Canadian Approval For Well Studied Probiotic 2ExeGi Pharma Secures Canadian Approval For Well Studied Probiotic 3
... 2011 ImaginAb, Inc. and Eurogentec S.A. announce ... for producing engineered antibody fragments. The two companies ... high-performance Pichia pastoris expression system. Leveraging ... the collaboration will accelerate the development of ImaginAb,s ...
... Jan. 31, 2011 Global Real Estate Consultants has ... a new facility in Fremont. Global ... provide insight and transparency in the Fremont commercial real ... Inc,s 350,000 sq. ft. state-of-the-art manufacturing facility with pilot ...
Cached Medicine Technology:ImaginAb, Inc. and Eurogentec S.A. Collaborate to Produce Antibody Fragments in Pichia 2Boehringer Ingelheim to Purchase Amgen's Fremont (USA) Facility 2
(Date:7/1/2015)... ... ... Incentivizing the use of generic drugs has been an easy way for plans ... off the prices for the brand-name products. But now that generics are experiencing record ... these high-cost generic drugs. The July issue of Atlantic Information Services, Inc.’s (AIS) The ...
(Date:7/1/2015)... ... July 01, 2015 , ... The Recovery Workforce Summit: 2015 PRA Annual ... editor of The Atlantic, as a keynote on June 2nd in Philadelphia, PA. Stossel ... his personal story added power and reach to the essential message, while opening doors ...
(Date:7/1/2015)... ... 01, 2015 , ... The executive team from Nutritional Products ... number of nutritional and beauty products, announced the company was successful in forging ... Sports Nutrition conference in Tampa, Florida. This specific ECRM trade show gives companies ...
(Date:7/1/2015)... (PRWEB) , ... July 01, 2015 , ... The Thule ... case was relentlessly tested to ensure it lived up to Thule’s rigorous standards. Due ... the protection and quality Thule owners have come to expect. , The ...
(Date:7/1/2015)... ... 2015 , ... AvePoint, the established leader in ... new operational office in Zurich, Switzerland. The new facility will deliver enterprise-level Microsoft ... for organizations throughout the Swiss market. , “AvePoint is committed to addressing ...
Breaking Medicine News(10 mins):Health News:Blues Execs Share Strategies for Managing Generic Drug Inflation in AIS Newsletter 2Health News:Blues Execs Share Strategies for Managing Generic Drug Inflation in AIS Newsletter 3Health News:Scott Stossel, Editor of The Atlantic, Addressed Mental Health Professionals on Reducing Prejudice and Discrimination 2Health News:Scott Stossel, Editor of The Atlantic, Addressed Mental Health Professionals on Reducing Prejudice and Discrimination 3Health News:Scott Stossel, Editor of The Atlantic, Addressed Mental Health Professionals on Reducing Prejudice and Discrimination 4Health News:Scott Stossel, Editor of The Atlantic, Addressed Mental Health Professionals on Reducing Prejudice and Discrimination 5Health News:NPI Executives Report Great Success at ECRM Conference 2Health News:AvePoint Opens Office in Zurich to Meet Increasing Market Demand for Enterprise Collaboration Solutions in Switzerland 2Health News:AvePoint Opens Office in Zurich to Meet Increasing Market Demand for Enterprise Collaboration Solutions in Switzerland 3
... a common cause of death among patients with pneumonia, sepsis ... The damage often occurs suddenly and can cause life-threatening breathing ... treatments. Patients usually are put on ventilators to give their ... doctors can do but wait and hope for the best. ...
... surface, a team of researchers from the University of ... Korean institutions have identified two distinct neuronal signaling pathways ... variety of skin diseases. One pathway produces the therapeutic ... effect. The findings, published in this week,s early ...
... at the University of Utah,s Comprehensive Arrhythmia and Research ... imaging (DE-MRI) holds promise for predicting the risks of ... U.S. Their latest study on a novel application of ... the Journal of the American College of Cardiology ...
... TUESDAY, Feb. 8 (HealthDay News) -- Teens who are already popular ... to bully other kids, new research suggests. The kids seem ... the eyes of their peers, according to the study, published in ... Researchers asked about 3,700 students in 8th, 9th and 10th grades ...
... of health inequalities between socio-economic groups has been noticed ... Organization, the World Bank and the United Nations Development ... importance and made this issue a priority. There is ... but have a particular impact on mental health. A ...
... This release is available in Spanish . ... the Spanish Higher Institute for Scientific Research (CSIC) have ... extensively employed in the development of cosmetic and drug ... of nanotechnology. Phospholipid vesicles (liposomes) are colloidal systems ...
Cached Medicine News:Health News:Gene protects lung from damage due to pneumonia, sepsis, trauma, transplants 2Health News:Gene protects lung from damage due to pneumonia, sepsis, trauma, transplants 3Health News:The hitch in the drug? The itch in the drug 2Health News:Study shows delayed-enhancement MRI may predict, prevent strokes 2Health News:Bullying May Accompany Drive to Be Popular 2Health News:Bullying May Accompany Drive to Be Popular 3Health News:Income inequalities are increasing the occurence of depression during financial crisis 2Health News:New data obtained on liposomes employed in drug encapsulation and gene therapies 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: